Frederiksen Simona D, Bekker-Nielsen Dunbar Maria, Snoer Agneta H, Deen Marie, Edvinsson Lars
Independent Researcher, Copenhagen, Denmark.
Independent Researcher, Salisbury, England.
Headache. 2020 Jun;60(6):1132-1164. doi: 10.1111/head.13802. Epub 2020 Apr 15.
OBJECTIVE: The aim of this systematic review and meta-analysis (SR-MA) was to identify signaling molecule profiles and blood-derived biomarkers in migraine and cluster headache (CH) patients. BACKGROUND: Currently no migraine and CH valid biomarkers are available. Blood tests based on biomarker profiles have been used to gather information about the nervous system. Such tests have not yet been established within the primary headache field. METHODS: Case-control and case-crossover studies investigating whole blood, plasma, and serum were identified worldwide. The qualitative synthesis focused on 9 signaling molecules (serotonin [5-HT], calcitonin gene-related peptide [CGRP], endothelin-1 [ET-1], neurokinin A, neurokinin B, neuropeptide Y, pituitary adenylate cyclase-activating peptide 38 [PACAP-38], substance P (SP), and vasoactive intestinal peptide) and the quantitative synthesis on 5-HT and CGRP (≥5 comparisons available). The meta-analysis was conducted using standard and 3-level random effect models. RESULTS: Fifty-four eligible studies were identified (87.0% migraine, 9.3% CH, 3.7% migraine, and CH), and 2768 headache patients and 1165 controls included. Comparable fluctuations of 5-HT, CGRP, ET-1, PACAP-38, and SP in blood were generally observed between migraine and CH. Significant findings were observed for some subgroups and strata, for example, higher interictal and ictal 5-HT venous blood levels (ratio of means = 1.32, 95% CI: 1.08; 1.61; ratio of means = 1.23, 95% CI: 1.01; 1.49) in episodic migraine with aura with a female-dominated case group, higher interictal CGRP blood levels in episodic migraine (ratio of means = 1.63, 95% CI: 1.18; 2.26), and chronic migraine (ratio of means = 1.89, 95% CI: 1.33; 2.68), and higher ictal CGRP blood levels (ratio of means = 1.35, 95% CI: 1.09; 1.68) in episodic migraine were observed. In most subgroups, the quantitative synthesis revealed a high degree of heterogeneity between studies in part explained by the blood sampling site, specimen source, blood specimen, and sex distribution. Other potential confounders were age, aura, study quality, menstrual cycle, and methodology (eg, storage temperature). CONCLUSIONS: Potential migraine and CH signaling molecule profiles and biomarkers were revealed. Nevertheless, the high degree of heterogeneity between studies impedes identification of valid biomarkers but allowed us to assess the presence of confounders. Consideration of the potential confounders identified in this SR-MA might be of importance in the experimental planning of future studies. This consideration could be incorporated through establishment of specific guidelines.
目的:本系统评价和荟萃分析(SR-MA)的目的是确定偏头痛和丛集性头痛(CH)患者的信号分子谱和血液衍生生物标志物。 背景:目前尚无用于偏头痛和丛集性头痛的有效生物标志物。基于生物标志物谱的血液检测已被用于收集有关神经系统的信息。此类检测在原发性头痛领域尚未建立。 方法:在全球范围内识别调查全血、血浆和血清的病例对照研究和病例交叉研究。定性综合分析聚焦于9种信号分子(血清素[5-HT]、降钙素基因相关肽[CGRP]、内皮素-1[ET-1]、神经激肽A、神经激肽B、神经肽Y、垂体腺苷酸环化酶激活肽38[PACAP-38]、P物质[SP]和血管活性肠肽),定量综合分析聚焦于5-HT和CGRP(有≥5项比较)。使用标准和三级随机效应模型进行荟萃分析。 结果:共识别出54项符合条件的研究(87.0%为偏头痛,9.3%为丛集性头痛,3.7%为偏头痛合并丛集性头痛),纳入2768例头痛患者和1165例对照。一般观察到偏头痛和丛集性头痛患者血液中5-HT、CGRP、ET-1、PACAP-38和SP有相似的波动。在一些亚组和分层中观察到显著结果,例如,在以女性为主的发作性偏头痛伴先兆病例组中,发作间期和发作期5-HT静脉血水平较高(均值比=1.32,95%CI:1.08;1.61;均值比=1.23,95%CI:1.01;1.49),发作性偏头痛(均值比=1.63,95%CI:1.18;2.26)和慢性偏头痛(均值比=1.89,95%CI:1.33;2.68)发作间期CGRP血液水平较高,发作性偏头痛发作期CGRP血液水平较高(均值比=1.35,95%CI:1.09;1.68)。在大多数亚组中,定量综合分析显示研究之间存在高度异质性,部分原因是血液采样部位、标本来源、血液标本和性别分布。其他潜在混杂因素包括年龄、先兆、研究质量、月经周期和方法(如储存温度)。 结论:揭示了潜在的偏头痛和丛集性头痛信号分子谱和生物标志物。然而,研究之间的高度异质性阻碍了有效生物标志物的识别,但使我们能够评估混杂因素的存在。在本SR-MA中确定的潜在混杂因素在未来研究的实验设计中可能很重要。可通过制定具体指南纳入这种考虑。
Curr Pain Headache Rep. 2017-4
J Headache Pain. 2018-7-13
J Headache Pain. 2016-12
J Headache Pain. 2025-2-20
Int J Mol Sci. 2023-7-26
Curr Pain Headache Rep. 2023-10